Understanding Kyprolis® (carfilzomib) for Injection

Kyprolis® (carfilzomib) is the second FDA-approved drug in a class of drugs called proteasome inhibitors, which block the activity of enzyme complexes called proteasomes. Proteasomes carry out the breakdown of proteins in a cell, a process that is necessary for the control of many critical cellular functions.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.